Brief: Clarity Pharmaceuticals Says FY Loss From Ordinary Activities After Tax Attributable A$23.8 Mln
24/08/2022 09:16
Aug 24 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* FY LOSS FROM ORDINARY ACTIVITIES AFTER TAX ATTRIBUTABLE
A$23.8
MILLION
* CASH AND CASH EQUIVALENT AS AT JUNE 30 A$55.3 MILLION
Source text for Eikon: ID:nASX4j2WZh
Further company coverage: CU6.AX
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial